Literature DB >> 28495917

Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.

Fabio Guolo1, Paola Minetto2, Marino Clavio2, Maurizio Miglino2, Federica Galaverna3, Anna Maria Raiola3, Carmen Di Grazia3, Nicoletta Colombo3, Sarah Pozzi3, Adalberto Ibatici3, Samuele Bagnasco2, Daniela Guardo2, Annalisa Kunkl4, Filippo Ballerini2, Chiara Ghiggi3, Roberto M Lemoli2, Marco Gobbi2, Andrea Bacigalupo5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28495917      PMCID： PMC5685236          DOI： 10.3324/haematol.2017.167254

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.

Authors:  Anna Candoni; Federico De Marchi; Francesca Zanini; Maria Elena Zannier; Erica Simeone; Eleonora Toffoletti; Alexsia Chiarvesio; Michela Cerno; Carla Filì; Francesca Patriarca; Renato Fanin
Journal:  Exp Hematol       Date:  2017-02-01       Impact factor: 3.084

Review 2.  Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia.

Authors:  Francesco Buccisano; Luca Maurillo; Maria Ilaria Del Principe; Giovanni Del Poeta; Giuseppe Sconocchia; Francesco Lo-Coco; William Arcese; Sergio Amadori; Adriano Venditti
Journal:  Blood       Date:  2011-10-28       Impact factor: 22.113

3.  Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial.

Authors:  John A Liu Yin; Michelle A O'Brien; Robert K Hills; Sarah B Daly; Keith Wheatley; Alan K Burnett
Journal:  Blood       Date:  2012-08-08       Impact factor: 22.113

4.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations.

Authors:  P Gorello; G Cazzaniga; F Alberti; M G Dell'Oro; E Gottardi; G Specchia; G Roti; R Rosati; M F Martelli; D Diverio; F Lo Coco; A Biondi; G Saglio; C Mecucci; B Falini
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

5.  High WT1 gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival.

Authors:  David A Jacobsohn; William T Tse; Stanley Chaleff; Alfred Rademaker; Reggie Duerst; Marie Olszewski; Wei Huang; Pauline M Chou; Morris Kletzel
Journal:  Br J Haematol       Date:  2009-07-23       Impact factor: 6.998

6.  Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia.

Authors:  Carlo Marani; Marino Clavio; Raffaella Grasso; Nicoletta Colombo; Fabio Guolo; Annalisa Kunkl; Filippo Ballerini; Livia Giannoni; Chiara Ghiggi; Giuseppina Fugazza; Jean-Louis Ravetti; Marco Gobbi; Maurizio Miglino
Journal:  Leuk Res       Date:  2013-07-23       Impact factor: 3.156

7.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Authors:  Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

8.  Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Authors:  Daisuke Araki; Brent L Wood; Megan Othus; Jerald P Radich; Anna B Halpern; Yi Zhou; Marco Mielcarek; Elihu H Estey; Frederick R Appelbaum; Roland B Walter
Journal:  J Clin Oncol       Date:  2015-12-14       Impact factor: 44.544

9.  Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.

Authors:  Mariana Bastos-Oreiro; Ana Perez-Corral; Carolina Martínez-Laperche; Leyre Bento; Cristina Pascual; Mi Kwon; Pascual Balsalobre; Cristina Muñoz; Elena Buces; David Serrano; Jorge Gayoso; Ismael Buño; Javier Anguita; José Luís Diéz-Martín
Journal:  Eur J Haematol       Date:  2014-04-29       Impact factor: 2.997

Review 10.  Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Authors:  David Grimwade; Sylvie D Freeman
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18
View more
  10 in total

1.  Minimal residual disease and stem cell transplantation outcomes.

Authors:  Jacqueline Cloos; Gert J Ossenkoppele; Richard Dillon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  Measurement of Residual Disease in Acute Myeloid Leukemia.

Authors:  Rahul S Vedula; R Coleman Lindsley
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 3.  The Prognostic Significance of Measurable ("Minimal") Residual Disease in Acute Myeloid Leukemia.

Authors:  Francesco Buccisano; Christopher S Hourigan; Roland B Walter
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

4.  Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia.

Authors:  Madlen Jentzsch; Marius Bill; Juliane Grimm; Julia Schulz; Stefanie Beinicke; Janine Häntschel; Karoline Goldmann; Wolfram Pönisch; Georg-Nikolaus Franke; Vladan Vucinic; Michael Cross; Gerhard Behre; Thoralf Lange; Dietger Niederwieser; Sebastian Schwind
Journal:  Hemasphere       Date:  2019-02-08

Review 5.  Strategies for minimal residual disease detection: current perspectives.

Authors:  Giacomo Andreani; Daniela Cilloni
Journal:  Blood Lymphat Cancer       Date:  2019-02-12

6.  Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease.

Authors:  Rita Tavarozzi; Enrica Manzato; Riccardo Morganti; Paola Sammuri; Giulia Tarrini; Federica Ricci; Giordana Mattana; Sara Galimberti; Mario Petrini; Giovanni Carulli
Journal:  Leuk Res Rep       Date:  2021-01-08

7.  Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.

Authors:  Charles Craddock; Aimee Jackson; Justin Loke; Shamyla Siddique; Andrea Hodgkinson; John Mason; Georgia Andrew; Sandeep Nagra; Ram Malladi; Andrew Peniket; Maria Gilleece; Rahuman Salim; Eleni Tholouli; Victoria Potter; Charles Crawley; Keith Wheatley; Rachel Protheroe; Paresh Vyas; Ann Hunter; Anne Parker; Keith Wilson; Jiri Pavlu; Jenny Byrne; Richard Dillon; Naeem Khan; Nicholas McCarthy; Sylvie D Freeman
Journal:  J Clin Oncol       Date:  2020-12-29       Impact factor: 44.544

Review 8.  The Role of Wilms' Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia.

Authors:  Davide Lazzarotto; Anna Candoni
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

Review 9.  Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease.

Authors:  Luca Maurillo; Renato Bassan; Nicola Cascavilla; Fabio Ciceri
Journal:  Cancers (Basel)       Date:  2019-09-23       Impact factor: 6.639

10.  CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program.

Authors:  Fabio Guolo; Luana Fianchi; Paola Minetto; Marino Clavio; Michele Gottardi; Sara Galimberti; Giuliana Rizzuto; Michela Rondoni; Giambattista Bertani; Michela Dargenio; Atto Bilio; Barbara Scappini; Patrizia Zappasodi; Anna Maria Scattolin; Francesco Grimaldi; Giuseppe Pietrantuono; Pellegrino Musto; Marco Cerrano; Stefano D'Ardia; Ernesta Audisio; Alessandro Cignetti; Crescenza Pasciolla; Francesca Pavesi; Anna Candoni; Carmela Gurreri; Monica Morselli; Caterina Alati; Nicola Fracchiolla; Giovanni Rossi; Manuela Caizzi; Fabrizio Carnevale-Schianca; Agostino Tafuri; Giuseppe Rossi; Felicetto Ferrara; Livio Pagano; Roberto Massimo Lemoli
Journal:  Blood Cancer J       Date:  2020-10-06       Impact factor: 11.037
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.